UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 70

Sortiert nach

P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS5102-TPS5102

2023

Volltextzugriff (PDF)

Characteristics of preceding trials associated with the outcome of subsequent phase III (P3) trials of targeted and immunological therapies in advanced cancers

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14576-e14576

2019

Volltextzugriff (PDF)

What do oncologists think patients with incurable cancer should be told about their prognosis? A survey of medical oncologists in Australia and New Zealand

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e22139-e22139

2018

Volltextzugriff (PDF)

Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC)

Journal of clinical oncology, 2022-06, Vol.40 (17_suppl), p.LBA5004-LBA5004

2022

Volltextzugriff (PDF)

Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A phase II trial (ANZUP1601)

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.TPS367-TPS367

2021

Volltextzugriff (PDF)

Comparison of efficacy and tolerability of weekly adjuvant chemotherapy for colorectal cancer (CRC) using folinic acid with fluorouracil dosed at 425 mg/m 2 or 370 mg/m 2

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e15134-e15134

2016

Volltextzugriff (PDF)

TheraP: A randomized phase II trial of [ 177 Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.TPS332-TPS332

2019

Volltextzugriff (PDF)

P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs)

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.TPS539-TPS539

2019

Volltextzugriff (PDF)

Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial

Journal of clinical oncology, 2019-06, Vol.37 (18_suppl), p.LBA2-LBA2

2019

Volltextzugriff (PDF)

Randomised phase III trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised, high risk, or node-positive prostate cancer: ENZARAD (ANZUP 1303)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS5096-TPS5096

2017

Volltextzugriff (PDF)

P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS4596-TPS4596

2018

Volltextzugriff (PDF)

Effect Sizes Hypothesized and Observed in Contemporary Phase III Trials of Targeted and Immunological Therapies for Advanced Cancer

JNCI cancer spectrum, 2018-10, Vol.2 (4), p.pky037-pky037

2018

Volltextzugriff (PDF)

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.TPS156-TPS156

2018

Volltextzugriff (PDF)

P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.TPS574-TPS574

2018

Volltextzugriff (PDF)

Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: The ANZUP ENZAMET Trial (ANZUP 1304)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS5090-TPS5090

2016

Volltextzugriff (PDF)

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high-risk or node-positive prostate cancer: ENZARAD (ANZUP 1303)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS5086-TPS5086

2016

Volltextzugriff (PDF)

P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS4592-TPS4592

2017

Volltextzugriff (PDF)

Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumors: updated analysis of an Australian multicenter phase II trial

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e16056-e16056

2016

Volltextzugriff (PDF)

Change in neutrophil to lymphocyte ratio as a prognostic and predictive marker in response to targeted therapy for metastatic renal cell carcinoma

Journal of clinical oncology, 2015-03, Vol.33 (7_suppl), p.404-404

2015

Volltextzugriff (PDF)

A role for repression in the wingless signalling pathway in drosophila melanogaster

Lawrence, Nicola Jane

2001

Volltextzugriff (PDF)

Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

The New England journal of medicine, 2023-04, Vol.388 (17), p.1547-1558

2023

Volltextzugriff (PDF)

Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis

Cochrane database of systematic reviews, 2019-09, Vol.9 (9), p.CD013103-CD013103

2019

Volltextzugriff (PDF)

Essential medicines for cancer: WHO recommendations and national priorities

Bulletin of the World Health Organization, 2016-10, Vol.94 (10), p.735-742

2016

Volltextzugriff (PDF)

Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis

Cochrane database of systematic reviews, 2021-06, Vol.6 (6), p.CD013156-CD013156

2021

Volltextzugriff (PDF)

1 – 25 von 70

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(67)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(41)
Life Sciences & Biomedicine
(39)
Humans
(36)
Male
(18)
General & Internal Medicine
(17)
Middle Aged
(15)
Medicine, General & Internal
(14)
Female
(12)
Aged
(11)
Medicin Och Hälsovetenskap
(11)
Patients
(11)
Oncology
(8)
Prostate Cancer
(8)
Randomized Controlled Trials As Topic
(8)
Treatment Outcome
(8)
Adult
(7)
Gastroenterology & Hepatology
(7)
Liver Disorders
(7)
Medicine General & Introductory Medical Sciences
(7)
Network Meta-Analysis
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)

Characteristics of preceding trials associated with the outcome of subsequent phase III (P3) trials of targeted and immunological therapies in advanced cancers

What do oncologists think patients with incurable cancer should be told about their prognosis? A survey of medical oncologists in Australia and New Zealand

Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC)

Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A phase II trial (ANZUP1601)

Comparison of efficacy and tolerability of weekly adjuvant chemotherapy for colorectal cancer (CRC) using folinic acid with fluorouracil dosed at 425 mg/m 2 or 370 mg/m 2

TheraP: A randomized phase II trial of [ 177 Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer

P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs)

Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial

Randomised phase III trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised, high risk, or node-positive prostate cancer: ENZARAD (ANZUP 1303)

P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs)

Effect Sizes Hypothesized and Observed in Contemporary Phase III Trials of Targeted and Immunological Therapies for Advanced Cancer

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303)

P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs)

Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: The ANZUP ENZAMET Trial (ANZUP 1304)

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high-risk or node-positive prostate cancer: ENZARAD (ANZUP 1303)

P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs)

Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumors: updated analysis of an Australian multicenter phase II trial

Change in neutrophil to lymphocyte ratio as a prognostic and predictive marker in response to targeted therapy for metastatic renal cell carcinoma

A role for repression in the wingless signalling pathway in drosophila melanogaster

Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis

Essential medicines for cancer: WHO recommendations and national priorities

Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis

Suchergebnisse filtern